Zymeworks Inc
F:0OX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Zymeworks Inc
Free Cash Flow
Zymeworks Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zymeworks Inc
F:0OX
|
Free Cash Flow
-$122.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Free Cash Flow
-$3.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-23%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Free Cash Flow
-$70.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-80%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Free Cash Flow
$119.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Free Cash Flow
-$253.3m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
-31%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Free Cash Flow
-CA$9.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-80%
|
CAGR 10-Years
0%
|
|
Zymeworks Inc
Glance View
Zymeworks Inc., a clinical-stage biopharmaceutical company, is on a mission to redefine the treatment landscape for serious diseases through its innovative approach to protein engineering and therapeutics. Established in Canada, Zymeworks is at the forefront of creating multifunctional therapeutics designed to combat cancer and other complex diseases. Central to its operation is the proprietary Azymetric™ platform, an advanced technology that enables the development of bispecific antibodies. This platform allows the creation of drugs that can simultaneously target two distinct antigens, vastly improving therapeutic efficacy and minimizing side effects. This groundbreaking technology represents a convergence of advanced science and tailored medicine, with applications that could fundamentally change patient outcomes in oncology and beyond. The business model of Zymeworks is multifaceted, involving both in-house development of therapeutic candidates and collaborative partnerships with major pharmaceutical firms. Revenue generation is primarily driven through strategic alliances, where Zymeworks licenses its technology platforms to industry giants like Merck and Eli Lilly in exchange for milestone payments, royalties, and research funding. These partnerships not only provide financial resources but also validate Zymeworks' scientific advancements and accelerate the global reach of its innovations. Additionally, Zymeworks’ pursuit of developing its own pipeline of drug candidates signifies a dual-path strategy; this not only diversifies its income streams but also positions the company as a leader in the next wave of antibody therapeutics. By effectively leveraging their technology in-house, while capitalizing on external partnerships, Zymeworks seeks to establish a lasting impact in the world of biopharmaceuticals.
See Also
What is Zymeworks Inc's Free Cash Flow?
Free Cash Flow
-122.4m
USD
Based on the financial report for Dec 31, 2023, Zymeworks Inc's Free Cash Flow amounts to -122.4m USD.
What is Zymeworks Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
8%
The average annual Free Cash Flow growth rates for Zymeworks Inc have been 8% over the past three years .